We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Calls for Comment on RWE and MedSun Adverse Event Reporting
FDA Calls for Comment on RWE and MedSun Adverse Event Reporting
The FDA has called for suggestions for how it should make use of user fee funding for two data reporting projects — premarket real-world evidence (RWE) activities and the Medical Product Safety Network (MedSun) program, a national surveillance network to collect postmarket data on medical devices.